At the end of 2015 there were almost 600 new oncology-related molecules in late-stage development, so it is no surprise that two-years on, the number of therapeutic options in cancer care is growing, and with it the complexity of treatments available. Similarly, for the life science ...
In a 2-arm study, if several kits are present at the site when a refusal to randomize happened, the site knows these kits are of the same type and can later track subjects assigned to the same treatment, which increases the potential for unblinding through observed outcomes. In contrast, ...
Sep 19, 2024 BioPharma APAC Illumina and LGC Biosearch Technologies Forge Strategic Partnership to Advance Agricultural Genomics Sep 17, 2024 Pharmaphorum ESMO: Interview with Sven Schaffer Sep 9, 2024 OncLive FDA Approves TruSight Oncology Comprehensive Assay As Pan-Tumor Companion Diagnostic Sep ...
To find out more about Complete HealthVizion please click here.Image pharmaphorum Editor 3 October, 2018 behavioural science Oncology Sponsored Addressing the oncological ‘other’: How predictive analysis ...Get in-depth news, opinions and features on pharma and healthcare sent straight to your ...
Antimicrobial resistance (AMR) causes high levels of global mortality. There is a global need to develop new antimicrobials to replace those whose efficacy is being eroded, but limited incentive for companies to engage in R&D, and a limited pipeline
Albert Bourla: During anniversaries, you have a time to reflect on what happened, particularly in the first anniversary. It is always quite emotional, but no one, I think, would have expected in the middle of this pandemic that we would have a path to liberat...
Nipple color can temporarily change due to normal hormonal shifts, pregnancy, or breastfeeding. The same goes for nipple size and texture. Permanent changes in the nipple can also occur and are often seen with breast surgeries, weight loss, and aging. ...
Survivin (also named BIRC5) is a well-known cancer therapeutic target. Since its discovery more than two decades ago, the use of survivin as a target for cancer therapeutics has remained a central goal of survivin studies in the cancer field. Many studie
Hiroyuki Okuzawa (hereinafter Okuzawa):Daiichi Sankyo has defined its 2025 Vision as becoming a ‘global pharma innovator with a competitive advantage in oncology’. To achieve this target and steadily shift to further growth to achieve the 2030 Vision of an ‘innovative global healthcare company co...
Wenzel S, et al. Dupilumab in persistent asthma with elevated eosinophil levels. PavordID et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre,double-blind, placebo-controlled trial. Lancet 2012; 380: 651– 659.A GrayIdeapharma Com...